Indicaciones para el uso de terapia de reemplazo hormonal oral en mujeres
DOI:
https://doi.org/10.51481/amc.v49i1.289Palabras clave:
Terapia de reemplazo hormonal, síntomas vasomotores, atrofia urogenital, tromboembolismo, cáncer de seno invasivo, enfermedad cerebrovascularResumen
El uso de la terapia de reemplazo hormonal oral ha sido una controversia en los últimos años, como consecuencia de una serie de estudios aleatorios que contradicen los lineamientos anteriores. Algunos autores refi eren sus observaciones respecto a estas investigaciones, así como las limitaciones. Sin embargo, se demuestra que las únicas indicaciones que persisten para su uso son el tratamiento del síndrome menopáusico, al menor tiempo y la menor dosis posible, y como segunda elección, la osteoporosis. El objetivo de esta revisión es ofrecer un apoyo a los profesionales en medicina que prescriben terapia de reemplazo hormonal en mujeres menopáusicas mayores de 50 años.
Descargas
Citas
Harlap, S. The benefi ts and risks of hormone replacement therapy: An epidemiologic overview. Am J Obstet Gynecol 1992; 166:1986 – 1992
Ziel, H. Finkle, W. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975; 293: 1167 - 1170
Udoff, L. Continuous estrogen-progestin replacement therapy in postmenopausal women. UpToDate, Rose, BD (Ed), UpToDate, Wellesley, MA, 2003. Recuperado el 10 de octubre del 2003 de http:// www.uptodate.com
Archer, D. Pickar, J. Bottiglioni, F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxiprogesterone acetate. Obstet
Gynecol 1994;83: 686 - 692
The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA 1996; 275: 370 - 375
Clisham, R. Ziegler, D. Lozano, K. Judd, H. comparison of continuous versus sequential estrogen and progestin therapy in postmenopausal Women. Obstet Gynecol 1991; 77: 241 – 246
Eiken, P. Kolthoff, N. Compliance with 10 years oral hormonal replacement therapy. Maturitas 2002; 41: 81 - 86
American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 1992; 117:1038 - 1041
American College of Obstetricians and Gynecologists. Hormone replacement therapy. ACOG Technical Bulletin 166. Washington, DC:
ACOG 1992
Nanas, H. Katz, D. American College of Preventive Medicine Practical policy statement, perimenopausal and postmenopausal hormone replacement therapy. Am J Prev Med 1999; 17: 250 – 254
Mosca, L. Grundy, S. Judelson, D. King, K. Limacher, M. Oparil, S. Guide to preventive cardiology for women. Circulation 1999;99: 2480 - 2484
Grady, D. Rubin, S. Petitti, D. Hormone Therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016 – 1037
Grimes D; Lobo R. Perspectives on the women’s health initiative trial of hormone replacement therapy. Obstet Gynecol 2002; 100: 1344 - 1353
Keating. Cleary, P. Rossi, A. Zaslavsky, A. Ayanian, J. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999; 130: 545 - 553
Ravnikar, V. Compliance with hormone therapy. Am J Obstet Gynecol 1987; 156: 1332- 1334
Dawood, Y. Tidey, G. Menopause. Curr prob Obstet Gynecol Fertil 1993; 16: 169 - 208
Freedman, R. Pathophysiology and treatment of menopausal hot fl ashes. Semin Reprod Med 2005; 23: 117 – 125
Greendale, G. Reboussin, B. Hogan, P. Barnebei, V. Shumaker, S. Johnson, S. Barret-Connor, E. Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/ progestin intervention trial. Obstet Gynecol 1998; 92: 982 – 988.
Nelson, H. Commonly used types of postmenopausal estrogen for treatment of hot fl ashes. JAMA 2004; 291: 1610 – 1620
MacLennan, A. Lester, S. Moore, V. Terapia de reemplazo estrogénico por vía oral versus placebo para el tratamiento de los sofocos (Revisión Cochrane traducida) En: La Biblioteca Cochrane Plus, número 2, 2005. Oxford, Update Software Ltd. Recuperado el 5 de julio de 2005 de http://www.update-software.com
Barret-Connor, E. Estrogen and Estrogen – Progestogen replacement: therapy and cardiovascular diseases. Am J Med 1993; 95(Suppl 5A):
S – 43S
The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factor in postmenopausal women: the Postmenopausal Estrogen / Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199 – 208
Editorials. PEPI in Perspective. Good answers spawn pressing Questions. JAMA 1995; 273: 240 – 241.
Hulley S; Grady D; Bus T; Furberg C; Herrington D; Riggs BL; Vittinghoff E. Randomized trial el estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen / progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605 - 613
Grady D; Herrington D; Bittner V; Blumenthal R; Davidson M; Hlatky M; Hsia J; Hulley S; Herd A; Khan S; Newby LK; Waters D; Vitinghoff E; Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow - up (HERS II). JAMA 2002; 288: 49 - 57
Writing Group for the Women’s Health Initiative Investigators. Risk and benefi ts of estrogen plus progestin in health postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 2002; 288:321- 333
Liu, J. Menopausal hormone therapy: a paradigm shift? Fertil Steril 2003; 80: 494 - 495
The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogens in postmenopausal women with hysterectomy. The womens health initiative randomizad controlled Trial. JAMA 2004; 291: 1701 – 1712
Hulley, S. Grady, D. The WHI Estrogen-Alone Trial – Do Things Look Any Better? JAMA 2004, 291: 1769 - 1771
Sánchez, G. Carmona, L. Roque, M. Sánchez, L. Bonfi ll, X. Terapia de reemplazo hormonal para la prevención de enfermedades cardiovasculares en mujeres posmenopáusicas (Revisión Cochrane traducida) En: La Biblioteca Cochrane Plus, 2005. Oxford: Update Software Ltd. Recuperado el 7 de agosto de 2005 de http://www. update-software.com
U.S. Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationales. Ann Intern Med 2002; 137:834 - 839
Sociedad Norteamericana de Menopausia. Informe del panel asesor de la NAMS sobre la terapia hormonal de la posmenopáusica. Menopause 2003; 10: 6 - 12
Recommendation statement from the Canadian task force on preventive health care. Postmenopausal hormone replacement therapy for primary prevention of cardiovascular and cerebrovascular disease. CMAJ 2004; 170: 1388 - 1390
North American Menopause Society. Recommendations for estrogen and progesterone use in peri and postmenopausal women: October 2002 position statement of the North American Menopause Society. Menopause 2004; 11:589 - 600
Ballagh, S. vaginal hormone therapy for urogenital and menopausal symptoms. Sem Reprod Med 2005; 23: 126 – 140
SOGC Clinical Practice Guidelines. The detection and management of vaginal atrophy. J Obstet Gynecol Can 2004; 26: 503 – 508
Barnabei, V. Cochrane, B. Aragaki, A. Nygaard, I. Williams, S. McGovern, P. Menopausal symptoms and treatment-related effects of estrogen and progestin in the women’s health initiative. Obstet Gynecol 2005; 105: 1063 – 1073
Cardozo. L. Bachmann, G. McClish, D. Fonda, D. Birgerson, L. MetaAnalysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: Second Report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998; 92: 722 – 727
Bachmann, G. Nevadunsky, N. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000; 61: 3090 – 3096
Cardozo, L. Lose, G. McClish, D. Versi, E. Koning, H. A Systematic review of estrogens for recurrent urinary tract infections: Third report of the hormones and urogenital therapy committee. Int Urogynecol J 2001; 12: 15 – 20
Grady, D. Brown, J. Vittinghoff, E. Applegate, W. Varner, E. Snyder, T. Postmenopausal hormones and incontinence: The heart and estrogen/ progestin replacement study. Obstet Gynecol 2001; 97: 116 – 120
Moehrer, B. Hextall, A. Jackson, S. Estrógenos para la incontinencia urinaria en mujeres (Revisión Cochrane traducida) En: La Biblioteca Cochrane Plus, 2005 Número 3, Oxford: Update Software Ltd.
Recuperado el 2 de febrero de 2006 de http://www.update-software. com
Compton, J. Sex steroids and bone. Physiological Reviews 2001; 81: 420 - 437
Couley, J. Seeley, D. Ensrud, K. Ettinger, B. Black, D. Cummings, S. Estrogen replacement therapy and fractures in older women. Ann
Intern Med 1995; 122: 9 – 12
Cauley, J. Black, D. Barrett-Connor, E. Harris, F. Shields, K. Applegate, W. Cummings, R. Effects of hormones replacement therapy on clinical fractures and height loss: the heart and estrogen/ progestin replacement study (HERS). Am J Med 2001; 110: 442 – 450
Hulley, S. Furberg, C. Barrett-Connor, E. Cauley, J. Grady, D. Haskell, W. Noncardiovascular Disease Outcomes During 6.8 Years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002; 288: 58 – 64
Cauley, J. Robbins, J. Chen, Z. Cummings, S. Jackson, R. LaCroix, A. Effects of estrogen plus progestin on risk of fracture and bone mineral density. The women’s health initiative randomized trial. JAMA 2003; 290: 1729 - 1738
The Writing Group for the PEPI. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions ( PEPI) trial. JAMA 1996; 276: 1389 – 1396
Torgerson, D. Bell-Syer, S. Hormone replacement therapy and prevention of nonvertebral fractures. A meta-analysis of randomized trial. JAMA 2001; 285: 2891 – 2897
Wells, G. Tugwell, P. Shea, B. Guyatt, G. Peterson, J. Zytaruk, N. Meta-Analysis of the effi cacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endoc Reviews 2002; 23: 529 – 539
Banks, E. Beral, V. Reeves, G. Balkwill, A. Barnes, I. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA 2004; 291: 2212 – 2220
Greendale, G. Wells, B. Marcus, R. Barrett-Connor, E. How many women lose bone mineral density while taking hormone replacement therapy? Results from the postmenopausal estrogen/progestin interventions trial. Arch Intern Med 2000; 160: 3065 – 3071
Greendale, G. Espeland, M. Stone, S. Marcus, R. Barrett-Connor, E. Bone mass response to discontinuation of long-term hormone replacement therapy. Results from the postmenopausal estrogen/ progestin interventions (PEPI) safety follow-up study. Arch Intern Med 2002; 162: 665 – 672
Greenspan, S. Emkey, R. Bone, H. Weiss, S. Bell, N. Downs, R. Signifi cant differential effects of alendronate, estrogen or combination therapy of the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. Ann Intern Med 2002; 137: 875 – 883
Cheung, A. Feig, D. Kapral, M. Diàz, N. Dodin, S. and the Canadian task force on preventive health care. CMAJ 2004; 170: 1665 - 1667
Simon, J. Hsia, J. Cauley, J. Richard, C. Harris, F. Fong, J. Postmenopausal hormone therapy and risk of stroke. The heart and estrogen-progestin replacement study. Circulation 2001;103: 638 - 642
Wassertheil, S. Hendrix, S. Limacher, M. Heiss, G. Kooperberg, C.Baird, A. Effect of estrogen plus progestin on stroke in postmenopausal women. The women’s health initiative: a randomized trial. JAMA 2003, 289: 2673 – 2684
Million Women Study Collaborators. Breast cancer and hormonesreplacement therapy in the million women study. Lancet 2003; 362: 419 - 427
Anderson, G. Judd, H. Kaunitz, A. Barad, D. Beresford, S. Pettinger, M. Effects pf estrogen plus progestin on gynecologic cancers and associated diagnostic procedures. The women’s health initiative randomized trial. JAMA 2003; 290: 1739 – 1748
Risch, H. Postmenopausal estrogen – only, but not estrogen + progestin, was associated with increased risk of ovarian cancer. Evid based Obstet Gynecol 2003; 5: 53-54
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2008 Acta Médica Costarricense
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
